Viewing data from:

CHOLESTYRAMINE

ANDA

CHOLESTYRAMINE | A077204 | PH HEALTH LTD

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-10-21 | 2 NDCs

Highest NADAC/Unit

$0.9031

per ea

Lowest NADAC/Unit

$0.0954

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
49884046565CHOLESTYRAMINE PACKET	$0.9031	EA	Generic	—	2026-10-21
49884046566CHOLESTYRAMINE POWDER	$0.0954	GM	Generic	—	2026-10-21

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

PUROLITE LLCCHOLESTYRAMINE RESIN USP

DMF 73241988

ION EXCHANGE INDIA LTDCHOLESTYRAMINE RESIN USP (INDION 454)

DMF 231712009

PHAEX POLYMERS PRIVATE LTDCHOLESTYRAMINE RESIN USP AS IN

DMF 276072013

DOW CHEMICAL COInactiveCHOLESTYRAMINE USP

DMF 57591985

ROHM AND HAAS COInactiveCHOLESTYRAMINE RESIN, USP-AMBERLITE IRP-276

DMF 65061986

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 4GM RESIN/PACKET

0 patents0 exclusivities▴

POWDER;ORAL | Approved: Aug 26, 2005

No patent or exclusivity listings for this strength.

#002 — EQ 4GM RESIN/SCOOPFUL

0 patents0 exclusivities▾

POWDER;ORAL | Approved: Aug 26, 2005